A bacterial metabolite turns Candida from hypha back to yeast

Candida albicans exists in two forms and can move between them. As a hypha it invades tissue and damages it. As a single yeast cell it detaches and travels — that is the form that reaches the bloodstream and spreads an infection. The yeast-to-hypha transition has long been described. The way back, from hypha to yeast, was much less well understood, largely because it is hard to observe.

An Australian team led by Ana Traven, with Manasa Bharathwaj as first author, began with a tool: they developed an imaging assay that makes the transition visible and countable. Only with a measure in hand could they ask what accelerates it. The answer turned out to be gladiolin, a bacterial natural product.

The mechanism is not that the compound issues an instruction to the fungus. Gladiolin rewires its metabolism — the cells consume glucose faster and accumulate more ergosterol. Faster consumption means faster depletion of glucose in the surroundings, and a low sugar level quiets signalling through the Ras and cyclic AMP pathway. It is that drop which switches the fungus back to its yeast form.

The authors also identified the regulators on the fungal side. The glycolysis activators Tye7 and Gal4 set the timing of the transition and contribute to its acceleration, whereas Upc2, the activator of ergosterol synthesis, works the other way — it sustains hyphal elongation and represses the transition. The direction therefore depends on which of these programmes prevails.

The significance of the result reaches beyond one molecule. Gladiolin is made by bacteria, and Candida albicans lives on mucosal surfaces surrounded by bacteria. The work shows a concrete way in which microbial neighbours can influence whether a fungus stays put or moves on — and it does so not through a signal but through a change in the availability of sugar.

It is worth knowing why this direction of the transition was so poorly described until now. The yeast-to-hypha switch is visible down a microscope, because the cell puts out a long straight extension. The way back looks different: the hypha neither retracts nor disappears — ordinary yeast cells bud off its end, and nothing distinguishes them from cells that were never a hypha at all. Without a method that follows a single cell through time, the whole process is lost in the background.

The limits are worth stating. The study was done in culture, not in an organism. Showing that metabolic conditions favour the disseminating form is not the same as showing that gladiolin raises the risk of systemic infection in a patient. The authors write carefully about conditions that may promote dissemination.

For a reader who thinks of a bolete when they hear the word fungus, there is a more general thread here. Changing shape according to what is available in the surroundings is the rule among fungi, not the exception. The same capacity that lets a mycelium switch from spreading to fruiting decides, in this case, whether an infection stays local.

Evidence status — 29 August 2026

The paper appeared on 19 August 2026. In imaging and culture experiments with Candida albicans, gladiolin increased glucose consumption; the later fall in glucose signalling through Ras–cAMP accelerated the transition from hypha to yeast. Genetic experiments supported roles for the regulators Tye7, Gal4 and Upc2. There was no animal study or human treatment trial. Yeast cells can disseminate more readily, so reversing a hypha is not automatically the same as disarming an infection. The study reveals metabolic control of morphology and bacterial–fungal signalling; any therapeutic use remains a hypothesis requiring separate efficacy and safety tests.